Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours

Journal of Pathology

Volumn 189, Issue 1, 1999, Pages 53-59

  Evans, Mark F ^a   McDicken, Ian W ^a   Herrington, C Simon ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Chromosome abnormalities; Interphase cytogenetics; Ovarian tumours

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 17; CONTROLLED STUDY; CYSTADENOMA; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUMERICAL CHROMOSOME ABERRATION; OVARY TUMOR; PRIORITY JOURNAL; STROMA; X CHROMOSOME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; INTERPHASE; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; X CHROMOSOME;

EID: 0032840271     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199909)189:1<53::AID-PATH393>3.0.CO;2-U     Document Type: Article

References (35)

1. Goldgar DE, Rowe K, Lewis CM, et al. Genetic epidemiology of familial ovarian cancer in Utah. In: Sharp F, Mason P, Blackett T, Berek J, eds. Ovarian Cancer 3. London: Chapman & Hall, 1995; 13-21.
2. Russell P, Bannatyne P. Surgical Pathology of the Ovaries. London: Churchill Livingstone, 1989.
3. Stevens A, Lowe J. Gynaecological and obstetric pathology. In: Stevens A, Lowe J, eds. Pathology. London: Mosby, 1995; 361-386.
4. Kurman RJ, Trimble CC. The behavior of serous tumours of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993; 12: 120-127.
5. Wolf NG, Abdul-Karim FW, Schork NJ, Schwartz S. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Am J Pathol 1996; 149: 511-520.
6. Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 1993; 53: 4138-4142.
7. Jenkins RB, Bartelt D Jr, Stalboerger P, et al. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 1993; 71: 76-86.
8. Roberts CG, Tattersall MHN. Cytogenetic study of solid ovarian tumours. Cancer Genet Cytogenet 1990; 48: 243-253.
9. Bello MJ, Rey JA. Chromosome aberrations in metastatic ovarian cancer: relationship with abnormalities in primary tumors. Int J Cancer 1990; 45: 50-54.
10. Pejovic T. Genetic changes in ovarian cancer. Ann Med 1995; 27: 73-78.
11. Pejovic T, Himmelmann A, Heim S, et al. Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer 1992; 65: 282-286.
12. Foulkes WD, Black DM, Stamp GWH, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993; 54: 220-225.
13. Tavassoli M, Ruhrberg C, Beaumont V, et al. Whole chromosome 17 loss in ovarian cancer. Genes, Chromosomes Cancer 1993; 8: 195-198.
14. Pieretti M, Powell DE, Gallion HH, Case EA, Conways PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of ovarian tumors. Hum Pathol 1995; 26: 393-397.
15. Merajver DS, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 1995; 9: 439-443.
16. Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L, Pfleiderer A. Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation. Cancer 1993; 72: 2423-2432.
17. Gabra H, Watson JE, Taylor KJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996; 56: 950-954.
18. Reid T. Interphase cytogenetics and its role in molecular diagnostics of solid tumors. Am J Pathol 1998; 152: 325-327.
19. Foulkes WD, Trowsdale J. Isolating tumour suppressor genes relevant to ovarian carcinoma - the role of loss of heterozygosity. In: Sharp F, Mason P, Blackett T, Berek J, eds. Ovarian Cancer 3. London: Chapman & Hall, 1995; 23-38.
20. Herrington CS, Cooper K, McGee JO'D. Interphase cytogenetics: analysis of numerical chromosome aberrations in isolated cells. J Pathol 1995; 175; 283-295.
21. Southern SA, Evans MF, Herrington CS. Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. Cancer Res 1997; 57: 4210-4213.
22. Southern SA, Herrington CS. Assessment of intratumoral karyotypic heterogeneity by interphase cytogenetics in paraffin-wax sections. J Clin Pathol: Mol Pathol 1996; 49: M283-M289.
23. Harrison M, Magee HM, O'Loughlin J, Gorey TF, Dervan PA. Chromosome 1 aneusomy, identified by interphase cytogenetics in mammographically detected ductal carcinoma in situ of the breast. J Pathol 1995; 175: 303-309.
24. Wolman SR, Macoska JA, Micale MA, Sakr WA. An approach to definition of genetic alterations in prostate cancer. Diagn Mol Pathol 1992; 1: 192-199.
25. Southern SA, Herrington CS. Interphase karyotypic analysis of chromosomes 11, 17 and X in invasive squamous carcinoma of the cervix: morphological correlation with HPV infection. Int J Cancer 1997; 70: 502-507.
26. Diebold J, Deisenhofer I, Baretton GB, et al. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas. Lab Invest 1996; 75: 473-485.
27. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
28. Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage. Cancer 1992; 69: 2668-2675.
29. Demirel D, Rodolfo L, Fishman A, et al. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Cancer 1996; 77: 1494-1500.
30. Kaern J, Trope CG, Abeler V, Pettersen EO. Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment? In: Sharp F, Mason P, Blackett T, Berek J, eds. Ovarian Cancer 3. London: Chapman & Hall, 1995; 13-21.
31. Yang-Feng TL, Li SB, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosome Xp and 13q in human ovarian cancer. Int J Cancer 1992; 52: 575-580.
32. Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 1995; 26: 393-397.
33. Thompson FH, Emerson J, Alberts D, et al. Clonal chromosome abnormalities in 54 cases of ovarian cancer. Cancer Genet Cytogenet 1994; 73: 33-45.
34. Diebold J, Siegert S, Baretton GB, et al. Interphase cytogenetic analysis of mucinous ovarian neoplasms. Lab Invest 1997; 76: 661-670.
35. Liehr T, Stubinger A, Thoma K, Tulusan HA, Gebhart E. Comparative interphase cytogenetics using FISH on human ovarian carcinomas. Anticancer Res 1994; 14: 183-188.